Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 173

1.

Overexpression of Long-Chain Acyl-CoA Synthetase 5 Increases Fatty Acid Oxidation and Free Radical Formation While Attenuating Insulin Signaling in Primary Human Skeletal Myotubes.

Kwak HB, Woodlief TL, Green TD, Cox JH, Hickner RC, Neufer PD, Cortright RN.

Int J Environ Res Public Health. 2019 Mar 31;16(7). pii: E1157. doi: 10.3390/ijerph16071157.

2.

Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial.

Priddy FH, Lewis DJM, Gelderblom HC, Hassanin H, Streatfield C, LaBranche C, Hare J, Cox JH, Dally L, Bendel D, Montefiori D, Sayeed E, Ackland J, Gilmour J, Schnepp BC, Wright JF, Johnson P.

Lancet HIV. 2019 Apr;6(4):e230-e239. doi: 10.1016/S2352-3018(19)30003-7. Epub 2019 Mar 15. Erratum in: Lancet HIV. 2019 Apr 3;:.

3.

Multiplexed FluoroSpot for the Analysis of Dengue Virus- and Zika Virus-Specific and Cross-Reactive Memory B Cells.

Adam A, Woda M, Kounlavouth S, Rothman AL, Jarman RG, Cox JH, Ledgerwood JE, Gromowski GD, Currier JR, Friberg H, Mathew A.

J Immunol. 2018 Dec 15;201(12):3804-3814. doi: 10.4049/jimmunol.1800892. Epub 2018 Nov 9.

PMID:
30413671
4.

Sensory aspects of Tourette syndrome.

Cox JH, Seri S, Cavanna AE.

Neurosci Biobehav Rev. 2018 May;88:170-176. doi: 10.1016/j.neubiorev.2018.03.016. Epub 2018 Mar 17. Review.

PMID:
29559228
5.

Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials.

Gaudinski MR, Houser KV, Morabito KM, Hu Z, Yamshchikov G, Rothwell RS, Berkowitz N, Mendoza F, Saunders JG, Novik L, Hendel CS, Holman LA, Gordon IJ, Cox JH, Edupuganti S, McArthur MA, Rouphael NG, Lyke KE, Cummings GE, Sitar S, Bailer RT, Foreman BM, Burgomaster K, Pelc RS, Gordon DN, DeMaso CR, Dowd KA, Laurencot C, Schwartz RM, Mascola JR, Graham BS, Pierson TC, Ledgerwood JE, Chen GL; VRC 319; VRC 320 study teams.

Lancet. 2018 Feb 10;391(10120):552-562. doi: 10.1016/S0140-6736(17)33105-7. Epub 2017 Dec 5.

6.

Cryopreservation-related loss of antigen-specific IFNγ producing CD4+ T-cells can skew immunogenicity data in vaccine trials: Lessons from a malaria vaccine trial substudy.

Ford T, Wenden C, Mbekeani A, Dally L, Cox JH, Morin M, Winstone N, Hill AVS, Gilmour J, Ewer KJ.

Vaccine. 2017 Apr 4;35(15):1898-1906. doi: 10.1016/j.vaccine.2017.02.038. Epub 2017 Mar 9.

7.

First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.

Nyombayire J, Anzala O, Gazzard B, Karita E, Bergin P, Hayes P, Kopycinski J, Omosa-Manyonyi G, Jackson A, Bizimana J, Farah B, Sayeed E, Parks CL, Inoue M, Hironaka T, Hara H, Shu T, Matano T, Dally L, Barin B, Park H, Gilmour J, Lombardo A, Excler JL, Fast P, Laufer DS, Cox JH; S001 Study Team.

J Infect Dis. 2017 Jan 1;215(1):95-104. doi: 10.1093/infdis/jiw500. Epub 2016 Oct 17.

8.

Broad HIV-1 inhibition in vitro by vaccine-elicited CD8(+) T cells in African adults.

Mutua G, Farah B, Langat R, Indangasi J, Ogola S, Onsembe B, Kopycinski JT, Hayes P, Borthwick NJ, Ashraf A, Dally L, Barin B, Tillander A, Gilmour J, De Bont J, Crook A, Hannaman D, Cox JH, Anzala O, Fast PE, Reilly M, Chinyenze K, Jaoko W, Hanke T, Hiv-Core 004 Study Group T.

Mol Ther Methods Clin Dev. 2016 Aug 31;3:16061. doi: 10.1038/mtm.2016.61. eCollection 2016.

9.

A Phase 1 Study of 4 Live, Recombinant Human Cytomegalovirus Towne/Toledo Chimera Vaccines in Cytomegalovirus-Seronegative Men.

Adler SP, Manganello AM, Lee R, McVoy MA, Nixon DE, Plotkin S, Mocarski E, Cox JH, Fast PE, Nesterenko PA, Murray SE, Hill AB, Kemble G.

J Infect Dis. 2016 Nov 1;214(9):1341-1348. Epub 2016 Aug 11.

10.

Safety and efficacy of aripiprazole for the treatment of pediatric Tourette syndrome and other chronic tic disorders.

Cox JH, Seri S, Cavanna AE.

Pediatric Health Med Ther. 2016 Jun 27;7:57-64. doi: 10.2147/PHMT.S87121. eCollection 2016. Review.

11.

Adenovirus-based HIV-1 vaccine candidates tested in efficacy trials elicit CD8+ T cells with limited breadth of HIV-1 inhibition.

Hayes PJ, Cox JH, Coleman AR, Fernandez N, Bergin PJ, Kopycinski JT, Nitayaphan S, Pitisuttihum P, de Souza M, Duerr A, Morgan C, Gilmour JW.

AIDS. 2016 Jul 17;30(11):1703-12. doi: 10.1097/QAD.0000000000001122.

12.

Active site specificity profiling datasets of matrix metalloproteinases (MMPs) 1, 2, 3, 7, 8, 9, 12, 13 and 14.

Eckhard U, Huesgen PF, Schilling O, Bellac CL, Butler GS, Cox JH, Dufour A, Goebeler V, Kappelhoff R, Auf dem Keller U, Klein T, Lange PF, Marino G, Morrison CJ, Prudova A, Rodriguez D, Starr AE, Wang Y, Overall CM.

Data Brief. 2016 Feb 22;7:299-310. doi: 10.1016/j.dib.2016.02.036. eCollection 2016 Jun.

13.

Active site specificity profiling of the matrix metalloproteinase family: Proteomic identification of 4300 cleavage sites by nine MMPs explored with structural and synthetic peptide cleavage analyses.

Eckhard U, Huesgen PF, Schilling O, Bellac CL, Butler GS, Cox JH, Dufour A, Goebeler V, Kappelhoff R, Keller UAD, Klein T, Lange PF, Marino G, Morrison CJ, Prudova A, Rodriguez D, Starr AE, Wang Y, Overall CM.

Matrix Biol. 2016 Jan;49:37-60. doi: 10.1016/j.matbio.2015.09.003. Epub 2015 Sep 25.

14.

An influenza vaccine pill-can we swallow it?

Fast PE, Cox JH.

Lancet Infect Dis. 2015 Sep;15(9):992-993. doi: 10.1016/S1473-3099(15)00252-2. No abstract available.

PMID:
26333316
15.

Intellectual development is positively related to intrinsic motivation and course grades for female but not male students.

Cortright RN, Lujan HL, Cox JH, Cortright MA, Langworthy BM, Petta LM, Tanner CJ, DiCarlo SE.

Adv Physiol Educ. 2015 Sep;39(3):181-6. doi: 10.1152/advan.00117.2014.

16.

A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults.

Mpendo J, Mutua G, Nyombayire J, Ingabire R, Nanvubya A, Anzala O, Karita E, Hayes P, Kopycinski J, Dally L, Hannaman D, Egan MA, Eldridge JH, Syvertsen K, Lehrman J, Rasmussen B, Gilmour J, Cox JH, Fast PE, Schmidt C.

PLoS One. 2015 Aug 7;10(8):e0134287. doi: 10.1371/journal.pone.0134287. eCollection 2015.

17.

Irritability symptoms in Gilles de la Tourette syndrome.

Cox JH, Cavanna AE.

J Neuropsychiatry Clin Neurosci. 2015 Winter;27(1):42-7. doi: 10.1176/appi.neuropsych.13060143.

PMID:
25716486
18.

Clinical utility of implantable neurostimulation devices as adjunctive treatment of uncontrolled seizures.

Cox JH, Seri S, Cavanna AE.

Neuropsychiatr Dis Treat. 2014 Nov 14;10:2191-200. doi: 10.2147/NDT.S60854. eCollection 2014. Review.

19.

Audit of the management of the syphilis outbreak in Herefordshire 2011-2013.

Cox JH, Elliott E, Sivaprakasam V, Chima-Okereke C.

Int J STD AIDS. 2015 Apr;26(5):357-9. doi: 10.1177/0956462414538771. Epub 2014 Jun 9.

PMID:
24912537
20.

Network analyses reveal pervasive functional regulation between proteases in the human protease web.

Fortelny N, Cox JH, Kappelhoff R, Starr AE, Lange PF, Pavlidis P, Overall CM.

PLoS Biol. 2014 May 27;12(5):e1001869. doi: 10.1371/journal.pbio.1001869. eCollection 2014 May.

21.

Zonisamide as a treatment for partial epileptic seizures: a systematic review.

Cox JH, Seri S, Cavanna AE.

Adv Ther. 2014 Mar;31(3):276-88. doi: 10.1007/s12325-014-0104-1. Epub 2014 Feb 13. Review.

PMID:
24522856
22.

Antibody-mediated targeting of the Orai1 calcium channel inhibits T cell function.

Cox JH, Hussell S, Søndergaard H, Roepstorff K, Bui JV, Deer JR, Zhang J, Li ZG, Lamberth K, Kvist PH, Padkjær S, Haase C, Zahn S, Odegard VH.

PLoS One. 2013 Dec 23;8(12):e82944. doi: 10.1371/journal.pone.0082944. eCollection 2013.

23.

Clinical Guidelines on Long-Term Pharmacotherapy for Bipolar Disorder in Children and Adolescents.

Cox JH, Seri S, Cavanna AE.

J Clin Med. 2014 Jan 21;3(1):135-43. doi: 10.3390/jcm3010135. Review.

24.

Development of a luciferase based viral inhibition assay to evaluate vaccine induced CD8 T-cell responses.

Naarding MA, Fernandez N, Kappes JC, Hayes P, Ahmed T, Icyuz M, Edmonds TG, Bergin P, Anzala O, Hanke T, Clark L, Cox JH, Cormier E, Ochsenbauer C, Gilmour J.

J Immunol Methods. 2014 Jul;409:161-73. doi: 10.1016/j.jim.2013.11.021. Epub 2013 Nov 28.

25.

Higher levels of intrinsic motivation are related to higher levels of class performance for male but not female students.

Cortright RN, Lujan HL, Blumberg AJ, Cox JH, DiCarlo SE.

Adv Physiol Educ. 2013 Sep;37(3):227-32. doi: 10.1152/advan.00018.2013.

26.

Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteers.

Mehendale S, Thakar M, Sahay S, Kumar M, Shete A, Sathyamurthi P, Verma A, Kurle S, Shrotri A, Gilmour J, Goyal R, Dally L, Sayeed E, Zachariah D, Ackland J, Kochhar S, Cox JH, Excler JL, Kumaraswami V, Paranjape R, Ramanathan VD.

PLoS One. 2013;8(2):e55831. doi: 10.1371/journal.pone.0055831. Epub 2013 Feb 13.

27.

Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults.

Hayes P, Gilmour J, von Lieven A, Gill D, Clark L, Kopycinski J, Cheeseman H, Chung A, Alter G, Dally L, Zachariah D, Lombardo A, Ackland J, Sayeed E, Jackson A, Boffito M, Gazzard B, Fast PE, Cox JH, Laufer D.

Clin Vaccine Immunol. 2013 Mar;20(3):397-408. doi: 10.1128/CVI.00637-12. Epub 2013 Jan 23.

28.

Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens.

Ratto-Kim S, Currier JR, Cox JH, Excler JL, Valencia-Micolta A, Thelian D, Lo V, Sayeed E, Polonis VR, Earl PL, Moss B, Robb ML, Michael NL, Kim JH, Marovich MA.

PLoS One. 2012;7(9):e45840. doi: 10.1371/journal.pone.0045840. Epub 2012 Sep 26.

29.

A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.

Keefer MC, Gilmour J, Hayes P, Gill D, Kopycinski J, Cheeseman H, Cashin-Cox M, Naarding M, Clark L, Fernandez N, Bunce CA, Hay CM, Welsh S, Komaroff W, Hachaambwa L, Tarragona-Fiol T, Sayeed E, Zachariah D, Ackland J, Loughran K, Barin B, Cormier E, Cox JH, Fast P, Excler JL.

PLoS One. 2012;7(8):e41936. doi: 10.1371/journal.pone.0041936. Epub 2012 Aug 3.

30.

A DNA-based candidate HIV vaccine delivered via in vivo electroporation induces CD4 responses toward the α4β7-binding V2 loop of HIV gp120 in healthy volunteers.

Kopycinski J, Cheeseman H, Ashraf A, Gill D, Hayes P, Hannaman D, Gilmour J, Cox JH, Vasan S.

Clin Vaccine Immunol. 2012 Sep;19(9):1557-9. doi: 10.1128/CVI.00327-12. Epub 2012 Jul 25.

31.

Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.

Cox JH, Ferrari MG, Earl P, Lane JR, Jagodzinski LL, Polonis VR, Kuta EG, Boyer JD, Ratto-Kim S, Eller LA, Pham DT, Hart L, Montefiori D, Ferrari G, Parrish S, Weiner DB, Moss B, Kim JH, Birx D, VanCott TC.

Vaccine. 2012 Feb 27;30(10):1830-40. doi: 10.1016/j.vaccine.2011.12.131. Epub 2012 Jan 9.

32.

Does sex (female versus male) influence the impact of class attendance on examination performance?

Cortright RN, Lujan HL, Cox JH, DiCarlo SE.

Adv Physiol Educ. 2011 Dec;35(4):416-20. doi: 10.1152/advan.00021.2011.

33.

Opposing consequences of IL-23 signaling mediated by innate and adaptive cells in chemically induced colitis in mice.

Cox JH, Kljavin NM, Ota N, Leonard J, Roose-Girma M, Diehl L, Ouyang W, Ghilardi N.

Mucosal Immunol. 2012 Jan;5(1):99-109. doi: 10.1038/mi.2011.54. Epub 2011 Nov 16.

PMID:
22089030
34.

Intra- and inter-clade cross-reactivity by HIV-1 Gag specific T-cells reveals exclusive and commonly targeted regions: implications for current vaccine trials.

Zembe L, Burgers WA, Jaspan HB, Bekker LG, Bredell H, Stevens G, Gilmour J, Cox JH, Fast P, Hayes P, Vardas E, Williamson C, Gray CM.

PLoS One. 2011;6(10):e26096. doi: 10.1371/journal.pone.0026096. Epub 2011 Oct 12.

35.

A double-blind randomized phase I clinical trial targeting ALVAC-HIV vaccine to human dendritic cells.

Eller MA, Slike BM, Cox JH, Lesho E, Wang Z, Currier JR, Darden JM, Polonis VR, Vahey MT, Peel S, Robb ML, Michael NL, Marovich MA.

PLoS One. 2011;6(9):e24254. doi: 10.1371/journal.pone.0024254. Epub 2011 Sep 16.

36.

In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers.

Vasan S, Hurley A, Schlesinger SJ, Hannaman D, Gardiner DF, Dugin DP, Boente-Carrera M, Vittorino R, Caskey M, Andersen J, Huang Y, Cox JH, Tarragona-Fiol T, Gill DK, Cheeseman H, Clark L, Dally L, Smith C, Schmidt C, Park HH, Kopycinski JT, Gilmour J, Fast P, Bernard R, Ho DD.

PLoS One. 2011;6(5):e19252. doi: 10.1371/journal.pone.0019252. Epub 2011 May 16.

37.

Progesterone increases skeletal muscle mitochondrial H2O2 emission in nonmenopausal women.

Kane DA, Lin CT, Anderson EJ, Kwak HB, Cox JH, Brophy PM, Hickner RC, Neufer PD, Cortright RN.

Am J Physiol Endocrinol Metab. 2011 Mar;300(3):E528-35. doi: 10.1152/ajpendo.00389.2010. Epub 2010 Dec 28.

38.

Equivalence of ELISpot assays demonstrated between major HIV network laboratories.

Gill DK, Huang Y, Levine GL, Sambor A, Carter DK, Sato A, Kopycinski J, Hayes P, Hahn B, Birungi J, Tarragona-Fiol T, Wan H, Randles M, Cooper AR, Ssemaganda A, Clark L, Kaleebu P, Self SG, Koup R, Wood B, McElrath MJ, Cox JH, Hural J, Gilmour J.

PLoS One. 2010 Dec 14;5(12):e14330. doi: 10.1371/journal.pone.0014330.

39.

IL-27 promotes T cell-dependent colitis through multiple mechanisms.

Cox JH, Kljavin NM, Ramamoorthi N, Diehl L, Batten M, Ghilardi N.

J Exp Med. 2011 Jan 17;208(1):115-23. doi: 10.1084/jem.20100410. Epub 2010 Dec 20.

40.

Matrix metalloproteinase 8 deficiency in mice exacerbates inflammatory arthritis through delayed neutrophil apoptosis and reduced caspase 11 expression.

Cox JH, Starr AE, Kappelhoff R, Yan R, Roberts CR, Overall CM.

Arthritis Rheum. 2010 Dec;62(12):3645-55. doi: 10.1002/art.27757.

41.

IL-27 supports germinal center function by enhancing IL-21 production and the function of T follicular helper cells.

Batten M, Ramamoorthi N, Kljavin NM, Ma CS, Cox JH, Dengler HS, Danilenko DM, Caplazi P, Wong M, Fulcher DA, Cook MC, King C, Tangye SG, de Sauvage FJ, Ghilardi N.

J Exp Med. 2010 Dec 20;207(13):2895-906. doi: 10.1084/jem.20100064. Epub 2010 Nov 22.

42.

Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate.

Currier JR, Ngauy V, de Souza MS, Ratto-Kim S, Cox JH, Polonis VR, Earl P, Moss B, Peel S, Slike B, Sriplienchan S, Thongcharoen P, Paris RM, Robb ML, Kim J, Michael NL, Marovich MA.

PLoS One. 2010 Nov 15;5(11):e13983. doi: 10.1371/journal.pone.0013983.

43.

Genetic dissection of interferon-antagonistic functions of rabies virus phosphoprotein: inhibition of interferon regulatory factor 3 activation is important for pathogenicity.

Rieder M, Brzózka K, Pfaller CK, Cox JH, Stitz L, Conzelmann KK.

J Virol. 2011 Jan;85(2):842-52. doi: 10.1128/JVI.01427-10. Epub 2010 Nov 17. Erratum in: J Virol. 2012 Apr;86(8):4720.

44.

Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa.

Jaoko W, Karita E, Kayitenkore K, Omosa-Manyonyi G, Allen S, Than S, Adams EM, Graham BS, Koup RA, Bailer RT, Smith C, Dally L, Farah B, Anzala O, Muvunyi CM, Bizimana J, Tarragona-Fiol T, Bergin PJ, Hayes P, Ho M, Loughran K, Komaroff W, Stevens G, Thomson H, Boaz MJ, Cox JH, Schmidt C, Gilmour J, Nabel GJ, Fast P, Bwayo J.

PLoS One. 2010 Sep 21;5(9):e12873. doi: 10.1371/journal.pone.0012873.

45.

Quality monitoring of HIV-1-infected and uninfected peripheral blood mononuclear cell samples in a resource-limited setting.

Olemukan RE, Eller LA, Ouma BJ, Etonu B, Erima S, Naluyima P, Kyabaggu D, Cox JH, Sandberg JK, Wabwire-Mangen F, Michael NL, Robb ML, de Souza MS, Eller MA.

Clin Vaccine Immunol. 2010 Jun;17(6):910-8. doi: 10.1128/CVI.00492-09. Epub 2010 Mar 3.

46.

A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172).

Kibuuka H, Kimutai R, Maboko L, Sawe F, Schunk MS, Kroidl A, Shaffer D, Eller LA, Kibaya R, Eller MA, Schindler KB, Schuetz A, Millard M, Kroll J, Dally L, Hoelscher M, Bailer R, Cox JH, Marovich M, Birx DL, Graham BS, Michael NL, de Souza MS, Robb ML.

J Infect Dis. 2010 Feb 15;201(4):600-7. doi: 10.1086/650299.

47.

Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines.

Earl PL, Cotter C, Moss B, VanCott T, Currier J, Eller LA, McCutchan F, Birx DL, Michael NL, Marovich MA, Robb M, Cox JH.

Vaccine. 2009 Sep 25;27(42):5885-95. doi: 10.1016/j.vaccine.2009.07.039. Epub 2009 Aug 3.

48.

Analysis of vaccine-virus-associated rabies cases in red foxes (Vulpes vulpes) after oral rabies vaccination campaigns in Germany and Austria.

Müller T, Bätza HJ, Beckert A, Bunzenthal C, Cox JH, Freuling CM, Fooks AR, Frost J, Geue L, Hoeflechner A, Marston D, Neubert A, Neubert L, Revilla-Fernández S, Vanek E, Vos A, Wodak E, Zimmer K, Mettenleiter TC.

Arch Virol. 2009;154(7):1081-91. doi: 10.1007/s00705-009-0408-7. Epub 2009 Jun 12.

PMID:
19521660
49.

Concordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continents.

Boaz MJ, Hayes P, Tarragona T, Seamons L, Cooper A, Birungi J, Kitandwe P, Semaganda A, Kaleebu P, Stevens G, Anzala O, Farah B, Ogola S, Indangasi J, Mhlanga P, Van Eeden M, Thakar M, Pujari A, Mishra S, Goonetilleke N, Moore S, Mahmoud A, Sathyamoorthy P, Mahalingam J, Narayanan PR, Ramanathan VD, Cox JH, Dally L, Gill DK, Gilmour J.

Clin Vaccine Immunol. 2009 Feb;16(2):147-55. doi: 10.1128/CVI.00326-08. Epub 2008 Dec 17.

50.

Supplemental Content

Support Center